MedTrace Logo

Apixaban for the Treatment of Venous Thromboembolism in Patients With Cancer

NCT03045406 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1170

Last updated 2025-06-24

Study results available
· View outcomes & findings →

Summary

Apixaban for the treatment of venous thromboembolism in patients with cancer: a prospective randomized open blinded end-point (PROBE) study

Conditions

  • Venous Thromboembolism

Interventions

DRUG

Apixaban

Tablets

DRUG

Dalteparin

Injections

Sponsors & Collaborators

  • University Of Perugia

    collaborator OTHER

  • Fadoi Foundation, Italy

    lead OTHER

Principal Investigators

  • Gualberto Gussoni, MD · FADOI Foundation

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-04-13
Primary Completion
2019-06-01
Completion
2019-12-01
FDA Drug
Yes

Countries

  • United States
  • Belgium
  • France
  • Germany
  • Israel
  • Italy
  • Netherlands
  • Poland
  • Portugal
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03045406 on ClinicalTrials.gov